Samumed said it has sold North American rights to its Phase I idiopathic pulmonary fibrosis (IPF) candidate SM04646 to United Therapeutics, in a deal that could generate more than $350 million for the privately-held San Diego biotech.
{iframe}https://www.genengnews.com/gen-news-highlights/united-therapeutics-acquires-north-american-rights-to-samumed-ipf-candidate-sm04646/81256243{/iframe}